Skip to main content

THE PRODUCTION OF A 3D HUMAN TISSUE DISEASE PLATFORM TO ENABLE REGENERATIVE MEDICINE THERAPY DEVELOPMENT

Objective

This project will focus on the production of an in vitro human disease tissue platform technology to enable and accelerate the development of regenerative medicine therapies for a diverse range of diseases. The concept will be realised by the in vitro generation of 3D human tissues cultured from human induced Pluripotent Stem (iPS) cells. Initially a library of adult cells will be generated from patients with a range of genetic diseases. These cells will subsequently be used to generate iPS cell cultures in optimised conditions, with the resultant cells being differentiated into key cell types. These differentiated cells will then be integrated onto 3D tissue bioreactors operating in an optimised variable perfusion environment producing the 3D human tissue disease cultures. The bioreactors will be constructed using a range of innovative microfluidic techniques to produce systems compatible with analysis systems commonly used in laboratories worldwide. The development of a platform technology producing 3D human tissue disease cultures will enable the generation of fully differentiated cell types and thus allow diseases to be effectively modelled at a population relevant scale in 3D human tissues in vitro. The resultant major benefit of the system is that it will allow regenerative therapies to be developed and tested on batteries of human tissues in the laboratory in a rapid, cost effective manner relevant to the in vivo state. To develop and validate the platform technology within the lifetime of the project liver hepatocyte cells and tissues will be generated due to their scientific and commercial significance from a population relevant range of patients with inherited metabolic disorders (IMDs). Therefore this project will significantly advance the state of the art and constitute a significant step forward for the regenerative medicine industry producing a key platform resource.

Field of science

  • /engineering and technology/environmental biotechnology/bioremediation/bioreactor

Call for proposal

FP7-HEALTH-2011-two-stage
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

Cn Bio Innovations Limited
Address
30 Upper High Street
OX9 3EZ Thame
United Kingdom
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 451 500
Administrative Contact
David Hughes (Dr.)

Participants (4)

Takara Bio Europe AB
Sweden
EU contribution
€ 1 216 325
Address
Arvid Wallgrens Backe
413 46 Göteborg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jenny Goodwin (Ms.)
TRANSTISSUE TECHNOLOGIES GMBH
Germany
EU contribution
€ 304 350
Address
Chariteplatz 1 / Virchowweg 11
10117 Berlin
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Christian Kaps (Dr.)
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 630 280
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Renata Schaeffer (Ms.)
MICRONIT MICROTECHNOLOGIES BV
Netherlands
EU contribution
€ 468 600
Address
Colosseum 15
7521 PV Enschede
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Rene Koopman (Mr.)